Back to top
Top

All eCQMs associated with: Management of Chronic Conditions

Year Type CMS eCQM ID Measure Name
2022 EH/CAH CMS122v10 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2023 EH/CAH CMS122v11 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2021 EH/CAH CMS122v9 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
2022 EH/CAH CMS131v10 Diabetes: Eye Exam
2023 EH/CAH CMS131v11 Diabetes: Eye Exam
2021 EH/CAH CMS131v9 Diabetes: Eye Exam
2022 EH/CAH CMS133v10 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2023 EH/CAH CMS133v11 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2021 EH/CAH CMS133v9 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
2022 EH/CAH CMS134v10 Diabetes: Medical Attention for Nephropathy
2021 EH/CAH CMS134v9 Diabetes: Medical Attention for Nephropathy
2022 EH/CAH CMS135v10 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2023 EH/CAH CMS135v11 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2021 EH/CAH CMS135v9 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2022 EH/CAH CMS143v10 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2023 EH/CAH CMS143v11 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2021 EH/CAH CMS143v9 Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
2022 EH/CAH CMS144v10 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2023 EH/CAH CMS144v11 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
2021 EH/CAH CMS144v9 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)